x

Posted 04 October, 2023

Emmaus Life Sciences, Inc. appointed new CEO

CEO Change detected for ticker OTC:EMMA in a 8-K filed on 04 October, 2023.


  On October 2, 2023, the Board of Directors of Emmaus Life Sciences, Inc. ("we," "us," "our," "Emmaus" or the "company") appointed George Sekulich to fill a vacancy on the Board of Directors created when Yutaka Niihara, M.D., M.P.H., the former Chairman and Chief Executive Officer, resigned as a director effective September 25, 2023.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Emmaus Life Sciences, Inc.
Business/Consumer Services • Computer Services
Emmaus Life Sciences, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. The company was founded on March 20, 1987 and is headquartered in Torrance, CA.
Market Cap
$5.90M
View Company Details
Emmaus Life Sciences, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers 


Appointment of Director


On October 2, 2023, the Board of Directors of Emmaus Life Sciences, Inc. ("we," "us," "our," "Emmaus" or the "company") appointed George Sekulich to fill a vacancy on the Board of Directors created when Yutaka Niihara, M.D., M.P.H., the former Chairman and Chief Executive Officer, resigned as a director effective September 25, 2023.


Mr. Sekulich, age 58, was recently appointed as Co-President and Chief Commercial Officer of the company and has served as Senior Vice President of Global Commercialization and Chief Information Officer since July 2019. From September 2014 through July 2019, Mr. Sekulich served as Chief Information Officer of EMI Holdings, Inc. (formerly, Emmaus Life Sciences, Inc.), our wholly owned subsidiary.


There are no family relationships between Mr. Sekulich and any of our other directors, executive officers, or persons nominated or chosen to become a director or executive officer. Mr. Sekulich is not party to any current or proposed transaction for which disclosure is required under Item 404(a) of Regulation S-K.


Also on October 2, 2023, the Board of Directors appointed Willis Lee, the Co-President and Chief Operating Officer, to serve as Chairman of the Board of Directors.